---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011938"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:55:00.184610+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez departs

## Summary
- Michelle Yanez and Telomir mutually agreed to her resignation as CFO, Treasurer, Secretary effective May 16, 2025; no disagreement.
- Alan Weichselbaum appointed CFO starting May 19, 2025; part-time role (30 hrs/week), salary $60,000/year.
- Weichselbaum receives 50,000 stock options vesting over 12 months (25k at 6 months, 25k at 12 months).
- Weichselbaum concurrently serves as CFO of MIRA Pharmaceuticals and CEO of Wexus Group.
- Employment is at-will, remote from New York, subject to background/reference check.

## SEC filing metadata
- accession: 0001641172-25-011938
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 5.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225011938/0001641172-25-011938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225011938/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011938
- JSON: https://secwatch.observer/filing/0001641172-25-011938.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011938.txt

## Key facts
- Executive change
  Michelle Yanez resigned as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of Telomir Pharmaceuticals, Inc. (the “Company”), effective on that date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000164117225011938/0001641172-25-011938-index.htm
- Executive change
  Alan Weichselbaum was appointed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 15, 2025, the Company entered into an Employment Agreement (the “Employment Agreement”) with Mr. Weichselbaum to serve as chief financial officer of the Company beginning on May 19, 2025 (the “Start Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000164117225011938/0001641172-25-011938-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.